Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled time : 12:30 save search
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
ADIL | $1.98 -8.76% 260K
|
Health Technology
|
| O: 123.48%
H: 0.0%
C: 0.0%
ad04 alcohol publication treatment pharmaceuticals for trial potential
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Published: 2024-04-08 (Crawled : 12:30) - prnewswire.com
NRXP 1 d | $3.065 1.49% 210K
|
Manufacturing
|
| O: 0.57%
H: 7.01%
C: 3.79%
nrx-101 depression treatment pharmaceuticals trial
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
Published: 2024-04-08 (Crawled : 12:30) - globenewswire.com
ENTX | $1.975 -11.83% 270K
|
Health Technology
|
| O: 2.3%
H: 1.25%
C: -2.5%
eb613 publication research bone trial
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NTRA S | $84.04 -3.71% 1.3M
|
Health Services
|
| O: 2.12%
H: 4.35%
C: 2.25%
bladder positive cancer trial
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:30) - globenewswire.com
EFTR | $1.645 -7.58% 170K
|
|
| O: -76.55%
H: 13.89%
C: -17.78%
lung cancer cell topline trial therapeutics results
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Published: 2024-04-03 (Crawled : 12:30) - prnewswire.com
GNPX | $2.2194 35K
|
Health Technology
|
| O: 1.76%
H: 13.15%
C: 7.61%
reqorsa lung cancer treat cell trial therapy study
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
Published: 2024-04-02 (Crawled : 12:30) - globenewswire.com
PRFX | News 0 d | $0.816 -8.32% 10K
|
Health Technology
|
| O: 9.2%
H: 0.0%
C: -8.95%
prf-110 trial
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
Published: 2024-04-01 (Crawled : 12:30) - globenewswire.com
VIRX | $0.909 41K
|
Manufacturing
|
| O: 0.96%
H: 8.57%
C: 5.71%
congress topline trial therapeutics results
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
Published: 2024-03-18 (Crawled : 12:30) - biospace.com/
NTRA S | $84.04 -3.71% 1.3M
|
Health Services
|
| O: 0.19%
H: 1.46%
C: 0.48%
cancer trial
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
Published: 2024-03-13 (Crawled : 12:30) - globenewswire.com
CMND | $1.215 3.13% 87K
|
n/a
|
| O: -2.72%
H: 1.4%
C: -4.9%
clearance trial
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
RGLS | $2.16 -2.7% 170K
|
Health Technology
|
| O: 68.84%
H: 62.66%
C: 1.29%
rgls8429 disease kidney positive treatment topline trial therapeutics
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
PFE A | $25.91 2.05% 22M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
adcetris positive trial
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
Published: 2024-03-11 (Crawled : 12:30) - globenewswire.com
DERM | $3.52 -1.68% 65K
|
|
| O: -1.45%
H: 0.88%
C: -0.88%
FBIO | $1.75 -3.32% 150K
|
Health Technology
|
| O: -0.48%
H: 2.87%
C: -4.31%
dfd-29 presentation corporation meeting impact medical trial
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
Published: 2024-03-07 (Crawled : 12:30) - globenewswire.com
MBIO | $0.356 -4.04% 130K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.75 -3.32% 150K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
mb-101 publication trial
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
Published: 2024-03-07 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.0354 320
|
Communications
|
| O: 0.79%
H: 0.78%
C: 0.78%
MBIO | $0.356 -4.04% 130K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.75 -3.32% 150K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
tumors cell city trial therapy
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
Published: 2024-03-06 (Crawled : 12:30) - globenewswire.com
KURA | $16.91 -4.35% 860K
|
Health Technology
|
| O: 1.28%
H: 8.54%
C: 6.52%
ko-2806 first renal cell trial plus
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
Published: 2024-03-05 (Crawled : 12:30) - biospace.com/
PODD | $164.07 -0.4% 310K
|
Health Technology
|
| O: 1.89%
H: 0.02%
C: -4.13%
omnipod first conference international trial advanced diabetes results
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Published: 2024-02-28 (Crawled : 12:30) - prnewswire.com
PTN | $1.87 -1.06% 110K
|
Health Technology
|
| O: -44.58%
H: 25.45%
C: 11.36%
pl9643 disease eye trial results
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Published: 2024-02-26 (Crawled : 12:30) - prnewswire.com
ATNM | $6.72 0.75% 220K
|
Health Technology
|
| O: 2.04%
H: 19.98%
C: 18.71%
astct active aml trial therapy
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
Published: 2024-02-26 (Crawled : 12:30) - globenewswire.com
KURA | $16.91 -4.35% 860K
|
Health Technology
|
| O: -0.15%
H: 4.01%
C: 2.57%
komet-008 first leukemia trial
Gainers vs Losers
| 70% | 30% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.